Wang Ying-Ying, Yang Wan-Xia, Cai Jiang-Ying, Wang Fang-Fang, You Chong-Ge
Laboratory Medicine Center, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, Gansu Province, 730030, China.
BMC Cancer. 2025 Mar 30;25(1):573. doi: 10.1186/s12885-025-13952-0.
The high heterogeneity of hepatocellular carcinoma (HCC) poses challenges for precision treatment strategies. This study aims to use multi-omics methodologies to better understand its pathogenesis and discover biomarkers.
Quantitative proteomics was used to investigate hepatocellular carcinoma tissues (HCT) and their corresponding adjacent non-tumor tissues (DNT), obtained from six HCC patients. Untargeted metabolomics was applied to analyze the metabolic profiles of HCT and DNT of ten HCC patients. Statistical analyses, such as the Student's t-test, were performed to identify differentially expressed proteins (DEPs) and metabolites (DEMs) between the two groups. The functions and metabolic pathways involving DEPs and DEMs were annotated and enriched using the gene ontology (GO) and kyoto encyclopedia of genes and genomes (KEGG) databases. Bioinformatics methods were then utilized to analyze consistency between proteomics and metabolomics results, leading to identification of potential biomarkers along with key altered pathways associated with HCC.
This study identified 1556 DEPs between HCT and DNT samples. These DEPs were primarily enriched in crucial biological pathways such as amino acid degradation, fatty acid metabolism, and DNA replication. Subsequently, the analysis of metabolomics identified 500 DEMs that mainly participated in glycerophospholipid metabolism, the phospholipase D signaling pathway, and choline metabolism related to cancer. Integrated analysis of proteomics and metabolomics data unveiled significant dysfunctions in bile secretion, multiple amino acid and fatty acid metabolic pathways among HCC patients. Further investigation revealed that five proteins (PTP4A3, B4GALT5, GAB1, ME2, and PKM) along with seven metabolites (PI(6 keto-PGF1alpha/16:0), 13, 16, 19-docosatrienoic acid, PA(18:2(9Z, 12Z)/20:1(11Z)), Citric Acid, PG(20:3(6, 8, 11)-OH(5)/18:2(9Z, 12Z)), Spermidine, and N2-Acetylornithine) exhibited excellent diagnostic efficiency for HCC and could serve as its potential biomarkers.
Our integrated proteome and metabolome analysis revealed 10 key HCC-related pathways and proposed 12 potential biomarkers, which may enhance our understanding of HCC pathophysiology and be helpful in facilitating early diagnosis and treatment strategies.
肝细胞癌(HCC)的高度异质性给精准治疗策略带来了挑战。本研究旨在使用多组学方法更好地理解其发病机制并发现生物标志物。
采用定量蛋白质组学研究从6例HCC患者获取的肝细胞癌组织(HCT)及其相应的癌旁非肿瘤组织(DNT)。应用非靶向代谢组学分析10例HCC患者的HCT和DNT的代谢谱。进行统计分析,如学生t检验,以鉴定两组之间差异表达的蛋白质(DEP)和代谢物(DEM)。使用基因本体论(GO)和京都基因与基因组百科全书(KEGG)数据库对涉及DEP和DEM的功能和代谢途径进行注释和富集。然后利用生物信息学方法分析蛋白质组学和代谢组学结果之间的一致性,从而鉴定潜在的生物标志物以及与HCC相关的关键改变途径。
本研究鉴定出HCT和DNT样本之间有1556个DEP。这些DEP主要富集于关键的生物学途径,如氨基酸降解、脂肪酸代谢和DNA复制。随后,代谢组学分析鉴定出500个DEM,它们主要参与甘油磷脂代谢、磷脂酶D信号通路以及与癌症相关的胆碱代谢。蛋白质组学和代谢组学数据的综合分析揭示了HCC患者胆汁分泌、多种氨基酸和脂肪酸代谢途径存在明显功能障碍。进一步研究发现,5种蛋白质(PTP4A3、B4GALT5、GAB1、ME2和PKM)以及7种代谢物(PI(6酮-PGF1α/16:0)、13,16,19-二十二碳三烯酸、PA(18:2(9Z,12Z)/20:1(11Z))、柠檬酸、PG(20:3(6,8,11)-OH(5)/18:2(9Z,12Z))、亚精胺和N2-乙酰鸟氨酸)对HCC具有优异的诊断效率,可作为其潜在的生物标志物。
我们的蛋白质组和代谢组综合分析揭示了10条与HCC相关的关键途径,并提出了12种潜在的生物标志物,这可能增进我们对HCC病理生理学的理解,并有助于促进早期诊断和治疗策略。